|
N
M Rothschild & Sons Limited ("Rothschild"),
which is authorised and regulated by the
Financial Services Authority in the United
Kingdom, acts for Oxford BioMedica plc and
no one else in relation to the contents
of this announcement and will not be responsible
to anyone other than Oxford BioMedica plc
for providing the protections afforded to
clients of Rothschild nor for providing
advice in relation to the contents of this
announcement.
|
| |
Oxford BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with a
focus on the areas of oncology and neurotherapy.
The Company was established in 1995 as a
spin out from Oxford University, and is
listed on the London Stock Exchange.
Oxford
BioMedica has core expertise in gene delivery,
as well as in-house clinical, regulatory
and manufacturing know-how. In oncology,
the pipeline includes an immunotherapy and
a gene therapy in multiple Phase II trials,
and a preclinical targeted antibody therapy
in collaboration with Wyeth. In neurotherapy,
the Company’s lead product is a gene
therapy for Parkinson’s disease, which
is expected to enter clinical development
in 2005, and four further preclinical candidates.
The Company is underpinned by over 80 patent
families, which represent one of the broadest
patent estates in the field.
The
Company has a staff of approx. 65 split
between its main facilities in Oxford and
its wholly owned subsidiary, BioMedica Inc,
in San Diego, California. Oxford BioMedica
has corporate collaborations with Wyeth,
Intervet, Amersham, Viragen, MolMed and
Kiadis; and has licensed technology to a
number of companies including Merck &
Co and Biogen Idec.
|
